Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Post-menopausal osteoporosis is a serious age-related disease. After the menopause, estrogen deficiency is common, and excessive osteoclast activity causes osteoporosis. Osteoclasts are multinucleated cells generated from the differentiation of monocyte/macrophage precursor cells such as RAW 264.7 cells. The water extract of Lycii Radicis Cortex (LRC) is made from the dried root bark of Lycium chinense Mill. and is termed 'Jigolpi' in Korea. Its effects on osteoclastogenesis and post‑menopausal osteoporosis had not previously been tested. In the present study, the effect of LRC on receptor activator of nuclear factor-κB (NF-κB) ligand (RANKL)-induced osteoclast differentiation was demonstrated using a tartrate-resistant acid phosphatase (TRAP) assay and pit formation assay. Moreover, in order to analyze molecular mechanisms, we studied osteoclastogenesis-related markers such as nuclear factor of activated T-cells cytoplasmic 1 (NFATc1), c-Fos, receptor activator of NF-κB (RANK), TRAP, cathepsin K (CTK), matrix metallopeptidase-9 (MMP-9), calcitonin receptor (CTR) and carbonic anhydrase Ⅱ (CAII) using RT-qPCR and western blot analysis. Additionally, we also determined the effect of LRC on an ovariectomized (OVX) rat model. We noted that LRC inhibited RANKL-induced osteoclast differentiation via suppressing osteoclastogenesis-related markers. It also inhibited osteoporosis in the OVX rat model by decreasing loss of bone density and trabecular area. These results suggest that LRC exerts a positive effect on menopausal osteoporosis.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4771095PMC
http://dx.doi.org/10.3892/ijmm.2016.2477DOI Listing

Publication Analysis

Top Keywords

rankl-induced osteoclast
12
osteoclast differentiation
12
lycii radicis
8
radicis cortex
8
raw 2647
8
2647 cells
8
receptor activator
8
osteoclastogenesis-related markers
8
ovx rat
8
rat model
8

Similar Publications

Dimethyl fumarate mitigates osteoarthritis progression through Nrf2 activation-mediated suppression of oxidative stress and subchondral osteoclastogenesis.

Int Immunopharmacol

September 2025

Department of Orthopaedics, The Second Affiliated Hospital and Yuying Childrens Hospital of Wenzhou Medical University, Wenzhou, Zhejiang Province, China; Key Laboratory of Orthopaedics of Zhejiang Province, Wenzhou, Zhejiang Province, China. Electronic address:

Osteoarthritis (OA) is a degenerative joint disease associated with imbalanced subchondral bone remodeling, and there is currently no curative treatment available. In OA, excessive osteoclast activity leads to bone loss and inflammatory responses. Dimethyl fumarate (DMF), an Nrf2 activator already used in treating psoriasis and multiple sclerosis, may alleviate OA by suppressing oxidative stress and osteoclastogenesis.

View Article and Find Full Text PDF

Sakuranetin inhibits osteoclastogenesis and rescues the ovariectomy-induced bone loss by blocking PI3K/AKT and NF-κB signaling pathway.

Int Immunopharmacol

September 2025

Department of Spine Surgery, Shanghai East Hospital, School of Medicine, Tongji University, Shanghai 200092, China. Electronic address:

Background: Bone remodeling constitutes an intricate physiological process essential for maintaining skeletal integrity. Hyperactivation of osteoclastogenesis precipitates excessive resorption of osseous tissue, consequently engendering osteoporotic pathology. The formulation of effective anti-resorptive therapeutic modalities remains a potential strategy in the clinical management of osteoporosis.

View Article and Find Full Text PDF

A novel HDAC1-specific inhibitor prevents estrogen deficiency-induced osteoporosis in mice by inhibiting osteoclast function.

Arch Gerontol Geriatr

August 2025

Department of Orthopedics Surgery, The Second Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou 310009, China; Orthopedics Research Institute of Zhejiang University, Hangzhou 310009, China; Key Laboratory of Motor System Disease Research and Precision Therapy of Zhejiang Provinc

Postmenopausal osteoporosis (PMOP) features reduced bone mass and deteriorated bone microstructure, increasing fracture risk. Estrogen deficiency-induced osteoclast overactivation is a primary driver. OCP-001, a novel highly selective HDAC1 inhibitor, was investigated.

View Article and Find Full Text PDF

Following dental extraction, alveolar bone loss, driven by the osteoclast (OC) bone-eroding cells, is a relevant concern in dental practice since it could compromise the possibility of installing dental implants. This study aimed to develop a drug delivery system releasing the antiosteoclastogenic molecule gallic acid (GA) at the alveolar bone level to control the dysregulated balance between OCs and bone-building osteoblasts and thus delay bone erosion. We functionalized small blocks of the hydroxyapatite- and β-tricalcium phosphate-based RIGENERA BTK BCP biomaterial with layered double hydroxide (LDH) and GA (RIG_LDH-GA).

View Article and Find Full Text PDF

Phloridzin, a natural compound derived from , exhibits a wide range of biological activities, making it a promising candidate for the development of functional foods aimed at promoting health and preventing disease. Gorham-Stout disease (GSD) is an orphan rare disorder defined by gradual bone resorption and vascular proliferation, with fewer than 400 cases documented, leading to severe pathological consequences. This study aims to examine the mechanisms underlying two key features of GSD, including progressive osteolysis, through osteoclastogenesis, and vascular proliferation, by examining endothelial and vascular cell proliferation.

View Article and Find Full Text PDF